Filing Flows › Comparisons › ANIP vs KNSA
ANI Pharmaceuticals vs Kiniksa Pharmaceuticals International: ANIP and KNSA compared
ANI Pharmaceuticals is the larger company: $291M of revenue in its latest quarter (Q3 2026) against $286M for Kiniksa Pharmaceuticals International (Q3 2026). Kiniksa Pharmaceuticals International is growing faster (+58% against +28% a year earlier). Kiniksa Pharmaceuticals International is more profitable, with an operating margin of 19.0% against 18.0%.
Where the money goes: ANIP and KNSA
ANI Pharmaceuticals (ANIP) · Q3 2026
ANI Pharmaceuticals, Q3 2026: revenue $291M (+28% year over year), operating margin 18.0%, net earnings $35.1M, operating cash flow $83.8M. The chart follows the revenue to costs, profit and cash.
Kiniksa Pharmaceuticals International (KNSA) · Q3 2026
Kiniksa Pharmaceuticals International, Q3 2026: revenue $286M (+58% year over year), operating margin 19.0%, net earnings $47.3M, operating cash flow $47.5M. The chart follows the revenue to costs, profit and cash.
| ANI Pharmaceuticals (ANIP) | Kiniksa Pharmaceuticals International (KNSA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $291M | $286M |
| Revenue growth, Y/Y | +28% | +58% |
| Operating margin | 18.0% | 19.0% |
| Net earnings | $35.1M | $47.3M |
| Net margin | 12.1% | 16.6% |
| Operating cash flow | $83.8M | $47.5M |
| Free cash flow | $70.3M | $47.4M |
| Market value | $1.5B | — |
| P/E | 13.7× | — |
| Analysts’ mean target | $105.78 | — |
Where the revenue comes from
ANI Pharmaceuticals
- Rare Disease and Brands total net revenues: $182M (63%)
- Generics and Other total net revenues: $108M (37%)
Questions
Which is bigger, ANI Pharmaceuticals or Kiniksa Pharmaceuticals International?
ANI Pharmaceuticals is the larger company: $291M of revenue in its latest quarter (Q3 2026) against $286M for Kiniksa Pharmaceuticals International (Q3 2026).
Is ANI Pharmaceuticals or Kiniksa Pharmaceuticals International growing faster?
Kiniksa Pharmaceuticals International is growing faster (+58% against +28% a year earlier).
Which is more profitable, ANI Pharmaceuticals or Kiniksa Pharmaceuticals International?
Kiniksa Pharmaceuticals International is more profitable, with an operating margin of 19.0% against 18.0%.
More: ANI Pharmaceuticals earnings · how ANI Pharmaceuticals makes money · Kiniksa Pharmaceuticals International earnings · how Kiniksa Pharmaceuticals International makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Oct 27, 2026). Fiscal quarters can end on different dates. Not investment advice.